- Home
- BXMX vs ATAI Comparison
BXMX vs ATAI Comparison
Compare BXMX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BXMX | ATAI |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BXMX | ATAI |
|---|---|---|
| Price | $14.69 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.86 |
| AVG Volume (30 Days) | 205.6K | ★ 4.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,018,000.00 |
| Revenue This Year | N/A | $962.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $11.75 | $1.15 |
| 52 Week High | $13.75 | $6.75 |
Technical Indicators
Market Signals| Indicator | BXMX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 57.09 |
| Support Level | $14.40 | $3.50 |
| Resistance Level | $14.78 | $3.85 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 56.82 | 99.34 |
Price Performance
Historical ComparisonAbout BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.